PFE241206P31000
- 5.12
- 0.000.00%
Pfizer Newsroom
Riot Shares Jump 13% as Activist Starboard Takes Stake in Bitcoin-Miner
Express News | Evonik Industries - to Organize Its Business Lines in Two New Segments: Custom Solutions and Advanced Technologies
Express News | Evonik Industries - to Reduce Number of Management Levels From Average of Ten to Maximum of Six by End of 2026
Express News | Evonik Industries - Both Segments Currently Have Annual Sales of Around EUR 6 Bln Each
Express News | Evonik Industries CEO: 2024 Is a Good Year for Evonik
Pfizer To Go Ex-Dividend On January 24th, 2025 With 0.43 USD Dividend Per Share
Pfizer announced an increase in the quarterly dividend.
The American pharmaceutical giant Pfizer announced on Thursday that it will increase the quarterly dividend by 2.4%, from 42 cents per share to 43 cents. The new dividend amounts to $1.72 per year, implying an annual yield of approximately 6.8%. Pfizer's CEO Albert Bourla stated that the increase in dividend highlights the company's strong financial performance, execution capabilities, and commitment to returning capital to shareholders.
Pfizer Boost Quarter Dividend by 2.4% to 43c
Express News | Pfizer Inc - Increases Quarterly Dividend to $0.43 per Share
Press Release: Pfizer Declares First-Quarter 2025 Dividend
Express News | Pfizer Declares First-Quarter 2025 Dividend
Pfizer Options Spot-On: On December 12th, 172.12K Contracts Were Traded, With 3.65 Million Open Interest
Thursday Ends in Index Declines | Wall Street Today
Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing
Market Falls Thursday, Producer Inflation Grows, and Tech Pulls Back From Records | LiveStock
CADL Stock Soars as Phase III Prostate Cancer Study Meets Primary Goal
Are Pfizer Inc.'s (NYSE:PFE) Mixed Financials Driving The Negative Sentiment?
Pfizer Announces Results From PATINA Trial
Express News | Pfizer Inc - Overall Survival Data Not yet Mature
Pfizer's IBRANCE in Combination With Standard-of-Care Therapies Extends Median Progression-Free Survival by Over 15 Months in Phase 3 PATINA Study in Patients With HR+, HER2+ Metastatic Breast Cancer